Wedbush Upgrades Spark Therapeutics, Inc. (NASDAQ:ONCE) From Underperform To Neutral With Target Price Of $ 40.00

Spark Therapeutics, Inc. (NASDAQ:ONCE) upgraded by Wedbush to Neutral from Underperform rating. The research firm sets target price at $ 40.00.

According to the previous trading day, closing price of ONCE was $ 41.68, representing a 6.84 % increase from the 52 week low of $ 39.01 and a 56.85 % decrease over the 52 week high of $ 96.59.

Spark Therapeutics, Inc. has a market capital of $ 1.64 billion and is part of the Healthcare sector and Biotechnology industry.

Be the first to comment

Leave a Reply